bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage lung cancer and other diseases of the lung. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is especially useful for patients whose lung cancer screening or other scan reveals a pulmonary nodule.
Our first product, CyPath® Flow Cytometry for Lung Cancer (CyPath® Lung), has been licensed by Precision Pathology Services for continued development and commercial sale as a Laboratory Developed Test.
CyPath® Lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.
Company Details
- Employees
- 31
- Founded
- -
- Address
- 3300 Nacogdoches Suite 216, San Antonio,texas 78217,united States
- Industry
- Biotechnology
- Website
- https://www.bioaffinitytech.com/
- HQ
- San Antonio, Texas
Bioaffinity Technologies Questions
Bioaffinity Technologies's website is https://www.bioaffinitytech.com/
Bioaffinity Technologies's LinkedIn profile is https://www.linkedin.com/company/bioaffinitytechnologies
Bioaffinity Technologies has
31 employees.
View email and phone details for 31
employees at Bioaffinity Technologies.
Bioaffinity Technologies's industry is
Biotechnology
Bioaffinity Technologies's top competitors are
Biodesix, Inc.,
Virax Biolabs,
Nexalin Technology,
Isomorphic Labs,
Sarepta Therapeutics,
Airna,
Allakos Inc,
Gamida Cell Ltd.,
Bluebird Bio,
Daiichi Sankyo.
Bioaffinity Technologies's categories are Biotechnology
Bioaffinity Technologies's founding year is 2014
